Upon exposure to anti-VEGF drugs, tumor cells increase the expression of other proangiogenic factors such as Fibroblast growth factor 1 (FGF-1) and FGF-2 (Brooks et al. 2012), TGF-β (Comunanza and Bussolino 2017), MMPs (Deryugina and Quigley 2010), angiopoietin-1 (Fagiani and Christofori 2013), Angiopoietin-2, Hepatocyte Growth Factor(HGF), Placental Growth Factor(PIGF) (Machado et al. 2023), ephrin-A1-2 (Zhuang et al. 2010), epidermal growth factor (Derynck et al. 1987) and stromal cell-derived factor 1 (SDF-1) (Batchelor et al. 2007). Here, VEGFA is linked to neoplasm.